Arcus Biosciences (RCUS) – Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Arcus Biosciences (NYSE: RCUS) in the last few weeks:

• 12/15/2025 – Arcus Biosciences had its “buy” rating reaffirmed by analysts at UBS Group AG.
• 12/14/2025 – Arcus Biosciences was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/12/2025 – Arcus Biosciences had its “buy” rating reaffirmed by analysts at Citigroup Inc..
• 12/12/2025 – Arcus Biosciences was given a new $30.00 price target on by analysts at Truist Financial Corporation.
• 12/12/2025 – Arcus Biosciences had its price target raised by analysts at HC Wainwright from $28.00 to $32.00. They now have a “buy” rating on the stock.
• 12/6/2025 – Arcus Biosciences was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/28/2025 – Arcus Biosciences had its price target raised by analysts at Bank of America Corporation from $17.00 to $26.00. They now have a “neutral” rating on the stock.
• 11/22/2025 – Arcus Biosciences was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/1/2025 – Arcus Biosciences was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.

Insiders Place Their Bets

In other news, COO Jennifer Jarrett sold 9,983 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $22.16, for a total transaction of $221,223.28. Following the completion of the transaction, the chief operating officer owned 193,024 shares in the company, valued at approximately $4,277,411.84. This represents a 4.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Richard Markus sold 4,494 shares of Arcus Biosciences stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $22.16, for a total value of $99,587.04. Following the transaction, the insider owned 65,647 shares in the company, valued at approximately $1,454,737.52. This trade represents a 6.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 433,977 shares of company stock worth $9,202,205. Company insiders own 9.60% of the company’s stock.

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.